Intercept Eyes EU NASH Market

 
• By Francesca Bruce

Analysts believe that pan-EU authorization for Intercept Pharmaceuticals’ obeticholic acid for advanced fibrosis due to nonalcoholic steatohepatitis may come in the first quarter of 2021.

ealthcare and pharmacy concept - different pills and capsules of drugs in shape of liver
Several companies are in the race to market a drug for NASH in the industrialized world

More from Product Reviews

More from Pink Sheet